FIG. 1




FIG. 2



PRVABC59 P1
log10 TCID50/mL
0
2
4
6
8
10
0
24
48
72
96
Time (hours post-infection)

FIG. 3



Average Log TCID50/mL
9,00
8,00
7,00
6,00
5,00
4,00
3,00
2,00
1,00
0,00
P5a PRVABC59
P5b PRVABC59
P5c PRVABC59
P5d PRVABC59
P5e PRVABC59
P5f PRVABC59
Titer
7,50
7,77
7,86
8,03
7,50
7,98

FIG. 4



Harvest 1
Harvest 2
Day 1
Day 2
Day 3
Day 5
P6a
P6b
P6c
P6d
P6e
P6f

FIG. 5



Absorbance
Microscope
plaque
Log TCID50/mL or PFU/mL
10.00
9.00
8.00
7.00
6.00
5.00
4.00
3.00
2.00
1.00
P6a
P6b
P6c
P6d
P6e
P6f
PRVABC59
PRVABC59
PRVABC59
PRVABC59
PRVABC59
PRVABC59
Absorbance 9.06 8.59 9.25 8.39 8.42 7.76
Microscope 8.42 8.67 8.50 8.33 8.64 7.92
plaque 7.00 7.63 7.33 7.30 7.34 7.33

FIG. 6




Env-330
ZIKV PRVABC59 P6e
ZIKV PRVABC59
WNV
JEV
SLEV
YFV
DENV 1 16007
DENV 2 16681
DENV 3 16562
DENV 4 1036

FIG. 7


NS1-98
ZIKV PRVABC59 P6e
ZIKV PRVABC59
WNV
JEV
SLEV
YFV
DENV 1 16007
DENV 2 16681
DENV 3 16562
DENV 4 1036




FIG. 8

FIG. 9



Plaque size
Average diameter (mm)
0
1
2
3
4
5
*
*
**
P1
P6a
P6b
P6c
P6d
P6e
P6f

FIG. 10



a
b
c
d
e
f
log10 TCID50/mL
10
8
6
4
2
0
0
24
48
72
96
120
Time (hours post infection)

FIG. 11



PIZV Kinetics of Inactivation
Log10 TCID50 and RNA Copy #
% CPE (COI)
Days Inactivation
TCID50
RNA Copy
COI
0
1
2
3
4
5
6
7
8
9
10
0
10
20
30
40
50
60
70
80
90
100

FIG. 12



Proportion +ve
0.275087
[0.19327,
0.37542]
1.0
0.8
0.6
0.4
0.2
0.0
C636
Vero
Vero
Sample Type
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
-0.5
Log10 (Concentration)
Proportion +ve
0.687247
[0.58111,
0.77682]
C636
Sample Type
Log10 (Concentration)

FIG. 13



Proportion +ve
0.008467
[0.00419,
0.01705]
1.0
0.8
0.6
0.4
0.2
0.0
C636
Vero
Sample Type
C636
-2.5
-2.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
Log10 (Concentration)
-2

FIG. 14




FIG. 15





FIG. 16


The percentage of intact Zika virus remaining after 10 days of storage (example 3A)
5 ± 3°C
- 80 °C
Percentage remaining / %
0
10
20
30
40
50
60
70
80
90
85
58
78
66
83
81
ZPB
Tris Buffer
Tris + Sucrose



The percentage of intact Zika virus remaining after 60 days of storage
(example 3B)
Percentage remaining / %
70
60
50
40
30
20
10
0
41
64
His
His + Sucrose
Buffer

FIG. 17

FIG. 18



The percentage of intact Zika virus remaining after 67 days of storage
(example 3C)
5 ± 3°C
- 80 °C
Percentage remaining / %
120
100
80
60
40
20
0
88
69
95
78
104
104
ZPB
Tris+Suc
Tris+10% Glycerol
Buffer

FIG. 19



The percentage of intact Zika virus remaining (measured by SEC) for Zika vaccine drug substance in ZPB and Tris+Suc, after storage for 3 months (corresponding to example 3D)
Percentage remaining / %
120
100
80
60
40
20
0
105
73
ZPB
Tris + Sucrose

FIG. 20




The percentage of intact Zika virus remaining for Zika vaccine drug substance in ZPB and TBS, after storage for 0 to 60 days (example 3E)
Percentage remaining / %
120
100
80
60
40
20
0
0
10
20
30
40
50
60
70
Time / days
ZPB
TBS

FIG. 21


The percentage of intact Zika virus remaining after repeated freeze-thaw cycles
(example 3F)
Percentage remaining / %
110
100
90
80
70
60
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Freeze thaw cycle
Tris + 3 % sucrose
Tris + 5 % sucrose
Tris + 7 % sucrose
Tris + 10 % sucrose